PE20221169A1 - USE OF A KV7 POTASSIUM CHANNEL OPENER TO TREAT PAIN - Google Patents

USE OF A KV7 POTASSIUM CHANNEL OPENER TO TREAT PAIN

Info

Publication number
PE20221169A1
PE20221169A1 PE2022001015A PE2022001015A PE20221169A1 PE 20221169 A1 PE20221169 A1 PE 20221169A1 PE 2022001015 A PE2022001015 A PE 2022001015A PE 2022001015 A PE2022001015 A PE 2022001015A PE 20221169 A1 PE20221169 A1 PE 20221169A1
Authority
PE
Peru
Prior art keywords
pain
compound
potassium channel
administration
methods
Prior art date
Application number
PE2022001015A
Other languages
Spanish (es)
Inventor
Jr James Philip Johnson
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PE20221169A1 publication Critical patent/PE20221169A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Esta referido a metodos para tratar el dolor, en donde los metodos comprenden administrar oralmente una cantidad efectiva terapeuticamente de N- 4-(6-fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil -3,3-dimetilbutanamida (Compuesto A), a un sujeto en necesidad de esta. La presente descripcion se dirige ademas a varios metodos mejorados de terapia y administracion del Compuesto A. El dolor tratado por la administracion del Compuesto A es dolor nociceptivo (como dolor radicular, dolor somatico, dolor visceral, dolor de tejido suave, dolor inflamatorio, dolor post operatorio, o una combinacion de estos), dolor neuropatico, o una combinacion de estos.It relates to methods of treating pain, wherein the methods comprise orally administering a therapeutically effective amount of N-4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl -3,3-dimethylbutanamide (Compound A), to a subject in need of it. The present disclosure is further directed to various improved methods of therapy and administration of Compound A. Pain treated by administration of Compound A is nociceptive pain (such as radicular pain, somatic pain, visceral pain, soft tissue pain, inflammatory pain, post operative, or a combination of these), neuropathic pain, or a combination of these.

PE2022001015A 2019-12-06 2020-12-04 USE OF A KV7 POTASSIUM CHANNEL OPENER TO TREAT PAIN PE20221169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
PE20221169A1 true PE20221169A1 (en) 2022-07-25

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001015A PE20221169A1 (en) 2019-12-06 2020-12-04 USE OF A KV7 POTASSIUM CHANNEL OPENER TO TREAT PAIN

Country Status (14)

Country Link
EP (1) EP4069211A1 (en)
JP (1) JP2023504166A (en)
KR (1) KR20220113411A (en)
CN (1) CN114786658A (en)
AU (1) AU2020397173A1 (en)
BR (1) BR112022010733A2 (en)
CA (1) CA3159436A1 (en)
CL (1) CL2022001477A1 (en)
CR (1) CR20220318A (en)
IL (1) IL293504A (en)
MX (1) MX2022006877A (en)
PE (1) PE20221169A1 (en)
TW (1) TW202133847A (en)
WO (1) WO2021113757A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698345B (en) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 Compounds as potassium channel modulators, their preparation and use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419691B2 (en) 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル Derivatives of 4- (N-azacycloalkyl) anilide as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
RS64922B1 (en) * 2018-05-11 2023-12-29 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
TW202133847A (en) 2021-09-16
KR20220113411A (en) 2022-08-12
CN114786658A (en) 2022-07-22
CL2022001477A1 (en) 2023-04-28
CA3159436A1 (en) 2021-06-10
CR20220318A (en) 2022-10-07
JP2023504166A (en) 2023-02-01
AU2020397173A1 (en) 2022-06-23
WO2021113757A1 (en) 2021-06-10
EP4069211A1 (en) 2022-10-12
MX2022006877A (en) 2022-07-11
BR112022010733A2 (en) 2022-08-23
IL293504A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
EA202092343A1 (en) TREATMENT OF PURULENT HYDRADENITIS WITH THE USE OF JAK INHIBITORS
MX2020004140A (en) Compositions and methods for the depletion of cd117+ cells.
ECSP088762A (en) PAIN TREATMENT
NZ726366A (en) Syk inhibitors
AR072442A1 (en) METHOD FOR CANCER THERAPY, USE, KIT
CO6410292A2 (en) 2-MERCAPTOQUINOLIN-3-SUBSTITUTED CARBOXAMIDS AS MODULATORS OF KCNQ2 / 3
MX2023007212A (en) Epinephrine spray formulations.
BR112021016833A2 (en) Compounds with ferroptosis-inducing activity and methods of their use
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
PE20221169A1 (en) USE OF A KV7 POTASSIUM CHANNEL OPENER TO TREAT PAIN
CL2023002549A1 (en) Certain pladienolide compounds and methods of use (divisional).
CL2022002813A1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis.
CO2019007879A2 (en) Crystalline forms of tebipenem pivoxil, compositions including them, manufacturing methods, and methods of use
CL2020002605A1 (en) Pladeniolide derivatives as splicing-targeting agents for treating cancer.
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
AR106538A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
CO2022008001A2 (en) Methods for treating depressive disorders
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
AR071779A1 (en) NARCOTIC EMULSION FORMULATIONS FOR THE SURGICAL PAIN TREATMENT
CL2023002321A1 (en) Voltage-activated potassium channel opener for use in the treatment of anhedonia.
PE20181450A1 (en) 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
EA202190798A1 (en) ROTAMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2-DITHIOL-3-THIONES
BR112022009794A2 (en) METHOD TO TREAT LUNG CANCER
MX2021011263A (en) Use of gabaa receptor modulators for treatment of pain.